-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
Biomarin Pharmaceutical Inc quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from 2013 to 2023.
- Biomarin Pharmaceutical Inc Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending March 31, 2024 was $106 M, a 86% increase year-over-year.
- Biomarin Pharmaceutical Inc Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending March 31, 2024 was $237 M, a 229% increase year-over-year.
- Biomarin Pharmaceutical Inc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was $189 M, a 26.1% increase from 2022.
- Biomarin Pharmaceutical Inc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was $150 M.
- Biomarin Pharmaceutical Inc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2021 was -$75.4 M, a 53.8% decline from 2020.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Growth (%)